Oppenheimer & CO Inc Amgen Inc Transaction History

Oppenheimer & CO Inc

  • $6.18 Billion
  • Q2 2024

A detailed history of Oppenheimer & CO Inc transactions in Amgen Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 123,638 shares of AMGN stock, worth $39.5 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares
123,638
Previous 121,155 2.05%
Holding current value
$39.5 Million
Previous $34.4 Million 12.15%
% of portfolio
0.62%
Previous 0.58%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024
BUY
$262.75 - $319.31 $652,408 - $792,846
2,483 Added 2.05%
123,638 $38.6 Million
Q1 2024

May 06, 2024
BUY
$268.87 - $324.56 $2.39 Million - $2.88 Million
8,874 Added 7.9%
121,155 $34.4 Million
Q4 2023

Feb 13, 2024
BUY
$255.7 - $288.46 $872,704 - $984,513
3,413 Added 3.13%
112,281 $32.3 Million
Q3 2023

Nov 07, 2023
BUY
$218.65 - $271.46 $579,641 - $719,640
2,651 Added 2.5%
108,868 $29.3 Million
Q2 2023

Aug 02, 2023
BUY
$214.27 - $253.37 $377,758 - $446,691
1,763 Added 1.69%
106,217 $23.6 Million
Q1 2023

May 10, 2023
BUY
$225.79 - $275.2 $3.8 Million - $4.64 Million
16,848 Added 19.23%
104,454 $25.3 Million
Q4 2022

Feb 07, 2023
SELL
$229.03 - $291.01 $1.43 Million - $1.82 Million
-6,259 Reduced 6.67%
87,606 $23 Million
Q3 2022

Nov 14, 2022
BUY
$224.46 - $253.15 $307,510 - $346,815
1,370 Added 1.48%
93,865 $21.2 Million
Q2 2022

Aug 08, 2022
SELL
$230.71 - $256.74 $644,373 - $717,074
-2,793 Reduced 2.93%
92,495 $22.5 Million
Q1 2022

May 12, 2022
SELL
$219.27 - $242.57 $469,895 - $519,827
-2,143 Reduced 2.2%
95,288 $23 Million
Q4 2021

Feb 02, 2022
BUY
$198.88 - $227.6 $945,276 - $1.08 Million
4,753 Added 5.13%
97,431 $21.9 Million
Q3 2021

Nov 12, 2021
SELL
$212.27 - $248.7 $276,163 - $323,558
-1,301 Reduced 1.38%
92,678 $19.7 Million
Q2 2021

Aug 03, 2021
BUY
$233.58 - $259.14 $340,326 - $377,566
1,457 Added 1.57%
93,979 $22.9 Million
Q1 2021

May 10, 2021
BUY
$221.91 - $258.6 $2.19 Million - $2.55 Million
9,879 Added 11.95%
92,522 $23 Million
Q4 2020

Feb 11, 2021
SELL
$216.38 - $257.67 $168,560 - $200,724
-779 Reduced 0.93%
82,643 $19 Million
Q3 2020

Nov 13, 2020
SELL
$234.65 - $260.95 $3.06 Million - $3.4 Million
-13,037 Reduced 13.52%
83,422 $21.2 Million
Q2 2020

Aug 11, 2020
SELL
$197.81 - $242.74 $3.42 Million - $4.2 Million
-17,306 Reduced 15.21%
96,459 $22.8 Million
Q1 2020

May 08, 2020
BUY
$182.24 - $241.7 $655,881 - $869,878
3,599 Added 3.27%
113,765 $23.1 Million
Q4 2019

Feb 07, 2020
SELL
$189.21 - $243.2 $320,710 - $412,224
-1,695 Reduced 1.52%
110,166 $26.6 Million
Q3 2019

Oct 31, 2019
BUY
$174.11 - $208.62 $109,341 - $131,013
628 Added 0.56%
111,861 $21.6 Million
Q2 2019

Aug 09, 2019
SELL
$166.7 - $195.41 $2.23 Million - $2.62 Million
-13,387 Reduced 10.74%
111,233 $20.5 Million
Q1 2019

Apr 24, 2019
SELL
$180.87 - $203.88 $100,021 - $112,745
-553 Reduced 0.44%
124,620 $23.7 Million
Q4 2018

Jan 29, 2019
SELL
$178.4 - $208.25 $427,803 - $499,383
-2,398 Reduced 1.88%
125,173 $24.4 Million
Q3 2018

Oct 26, 2018
SELL
$185.29 - $208.89 $763,580 - $860,835
-4,121 Reduced 3.13%
127,571 $26.4 Million
Q2 2018

Aug 10, 2018
SELL
$166.05 - $186.51 $212,377 - $238,546
-1,279 Reduced 0.96%
131,692 $24.3 Million
Q1 2018

May 01, 2018
SELL
$169.43 - $198.0 $3.08 Million - $3.6 Million
-18,175 Reduced 12.02%
132,971 $22.7 Million
Q4 2017

Feb 07, 2018
BUY
$168.79 - $188.59 $1.83 Million - $2.04 Million
10,834 Added 7.72%
151,146 $26.3 Million
Q3 2017

Nov 09, 2017
BUY
$167.29 - $191.0 $23.5 Million - $26.8 Million
140,312
140,312 $26.2 Million

Others Institutions Holding AMGN

# of Institutions
3,054
Shares Held
409M
Call Options Held
7.19M
Put Options Held
6.26M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $171B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email